Chippenham, UK – 23 May , 2007: Vectura Group plc (LSE: VEC) (“Vectura”), the pulmonary product development Company focused on respiratory and neurological diseases, today announces the successful outcome of a Phase IIa proof-of-concept clinical study for its product VR776 for the treatment of Premature Ejaculation (PE). The data demonstrate that VR776 improves intravaginal ejaculatory latency time (IVELT).
